GLP-1 receptor agonists — the class of medications that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — have reshaped the landscape of weight management. But as millions of people begin these therapies, a persistent question lingers: do these drugs cause significant muscle loss?
Early concerns suggested that the rapid weight loss triggered by GLP-1 drugs could erode lean muscle mass — a risk that worried clinicians and patients alike. Emerging research, however, is painting a more reassuring picture.
Understanding GLP-1 Receptor Agonists
GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed to treat type 2 diabetes. By mimicking a hormone released after eating, they suppress appetite, slow gastric emptying, and regulate blood sugar. Over time, clinical trials revealed their powerful weight-loss effects — and the FDA approved semaglutide (Wegovy) and tirzepatide (Zepbound) specifically for chronic weight management.
In landmark trials, participants lost an average of 15–22% of their body weight over 68 weeks — results previously only achievable through bariatric surgery.
The Muscle Loss Concern
With any significant calorie deficit, the body doesn’t exclusively burn fat. Research has long established that roughly 20–40% of weight lost through diet alone can come from lean tissue, including muscle. Given the rapid and dramatic weight loss seen with GLP-1 drugs, scientists raised alarms that muscle mass could take a disproportionate hit.
Muscle loss isn’t merely a cosmetic concern. Skeletal muscle plays a critical role in metabolic health — it’s the body’s primary site for glucose disposal, supports joint function, and contributes to long-term physical independence. A condition called sarcopenic obesity — where excess fat and reduced muscle coexist — is associated with higher risks of diabetes, falls, and cardiovascular disease.
What the Latest Research Shows
Several recent studies have offered more nuanced findings that challenge the worst-case scenarios about GLP-1 drugs and muscle loss.
The SURMOUNT Trials (Tirzepatide)
Data from the SURMOUNT-1 trial, published in the New England Journal of Medicine, showed that participants taking tirzepatide lost substantial body weight — but body composition analysis revealed that the vast majority of weight lost was adipose (fat) tissue, not lean mass. In fact, the proportion of lean mass relative to total body weight increased slightly in some groups, suggesting the drug may preferentially target fat stores.
DEXA Scan Data from STEP Trials (Semaglutide)
In the STEP 1 trial for semaglutide, dual-energy X-ray absorptiometry (DEXA) scans showed that while absolute lean mass did decrease — as expected with any large weight loss — the ratio of fat-free mass to total weight was preserved or even improved in many participants. Researchers noted this was comparable to what is typically seen following bariatric surgery, which is considered a gold standard for obesity treatment.
Muscle Function May Remain Intact
A 2025 review in Obesity Reviews analyzing pooled data from multiple GLP-1 trials found that while lean mass decreases in absolute terms, muscle function, strength, and physical performance scores were generally maintained — and sometimes improved — in study participants. The authors hypothesized that reduced body weight itself lightens the mechanical load on muscles, which may offset the effects of modest lean mass reduction.
Why Some Muscle Loss Still Occurs
Despite these encouraging signals, experts stress that some degree of lean mass loss is virtually inevitable with significant calorie restriction — regardless of the method. GLP-1 drugs work by dramatically reducing food intake, and insufficient protein consumption is a key driver of muscle breakdown during weight loss.
Studies indicate that many patients on GLP-1 drugs reduce their total calorie intake by 30–40%, and if protein intake falls proportionally, the body may turn to muscle as a fuel source. This is particularly relevant for older adults, who are already at risk for age-related muscle loss (sarcopenia) and may have less reserve to absorb this effect.
How to Protect Muscle Mass While on GLP-1 Therapy
Clinicians and researchers have begun issuing practical guidance for patients taking GLP-1 medications who want to preserve muscle. Research suggests several strategies may help:
1. Prioritize Protein Intake
Studies consistently show that higher protein diets during weight loss help preserve lean mass. Current evidence suggests aiming for 1.2 to 1.6 grams of protein per kilogram of body weight per day — significantly above the standard dietary recommendation of 0.8g/kg. Protein-rich foods include eggs, lean meats, fish, legumes, Greek yogurt, and tofu.
2. Incorporate Resistance Training
Progressive resistance exercise — lifting weights, using resistance bands, or performing bodyweight exercises — is the most effective intervention for maintaining and building muscle. A 2024 randomized controlled trial published in JAMA Internal Medicine found that participants who combined semaglutide with a structured resistance training program lost significantly more fat while preserving substantially more lean mass compared to those on the medication alone.
3. Avoid Extreme Caloric Deficits
While GLP-1 drugs suppress appetite aggressively, experts recommend resisting the temptation to eat as little as possible. A moderate calorie deficit — rather than severe restriction — helps the body prioritize fat burning over muscle catabolism. Consulting a registered dietitian can help calibrate a sustainable intake level.
4. Consider Creatine Supplementation
Emerging research suggests that creatine monohydrate, one of the most well-studied supplements in exercise science, may help preserve muscle and strength during calorie-restricted weight loss. While not specific to GLP-1 therapy, several sports medicine researchers have pointed to creatine as a low-risk adjunct for patients concerned about muscle preservation.
The Road Ahead: Muscle-Sparing GLP-1 Combinations
Pharmaceutical companies are actively developing next-generation therapies specifically designed to produce fat loss while protecting — or even building — muscle mass. Bimagrumab, an anti-myostatin antibody, has shown early promise in clinical trials when combined with semaglutide, producing dramatic reductions in fat mass with a measurable increase in lean mass. Amgen’s MariTide and several other pipeline candidates targeting both GLP-1 and GIP receptors are also being evaluated for superior body composition outcomes.
Additionally, researchers are exploring GLP-1 and GIP/glucagon triple agonists that may independently stimulate muscle protein synthesis while reducing fat — a combination that could make muscle loss a non-issue for future patients.
The Bottom Line
The fear that GLP-1 drugs cause devastating muscle loss appears to be overstated, according to the latest body of evidence. While some lean tissue reduction is expected with any significant weight loss, research suggests that GLP-1 receptor agonists preserve body composition at least as well — and possibly better — than other weight-loss approaches.
That said, the quality of weight lost matters as much as the quantity. Research suggests that combining GLP-1 therapy with adequate protein intake and resistance exercise is the most evidence-backed strategy for protecting muscle while achieving fat loss goals. Patients considering or currently taking these medications are strongly encouraged to discuss body composition goals with their healthcare team.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.